Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL605837 | 0.99 | HRH4 (0.60) | HRH4HTR3AUSP2LMNATSHR | |
| SCHEMBL18550556 | 0.92 | HRH4 (0.52) | HRH4HTR3AUSP2LMNATSHR | |
| SCHEMBL602797 | 0.88 | HRH4 (0.67) | HRH4HTR3AUSP2LMNATSHR | |
| SCHEMBL606443 | 0.88 | HRH4 (0.61) | HRH4HTR3AUSP2LMNATSHR | |
| SCHEMBL605957 | 0.88 | HRH4 (0.61) | HRH4HTR3AUSP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL607197 | 0.87 | HRH4 (0.66) | HRH4HTR3AUSP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL603172 | 0.87 | HRH4 (0.60) | HRH4HTR3AUSP2LMNATSHR | |
| Hydrochloric Acid SCHEMBL606452 | 0.87 | HRH4 (0.60) | HRH4HTR3AUSP2LMNATSHR | |
| SCHEMBL603123 | 0.87 | HRH4 (0.62) | HRH4HTR3AUSP2LMNATSHR | |
| SCHEMBL604702 | 0.86 | HRH4 (0.59) | HRH4USP2LMNATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005054239-A1 | 2-AMINOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-06-16 | — | — | WO | claimed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| EP-2858647-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013182711-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2013-12-12 | — | — | WO | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| WO-2005054239-A1 | 2-AMINOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-06-16 | — | — | WO | disclosed |